Psoriasis is associated with lipid abnormalities at the onset of skin disease

被引:258
作者
Mallbris, L
Granath, F
Hamsten, A
Ståhle, M
机构
[1] Karolinska Inst, Dept Med, King Gustaf V Res Inst, Unit Dermatol, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Med, King Gustaf V Res Inst, Clin Epidemiol Unit, S-17176 Stockholm, Sweden
[3] Karolinska Inst, Dept Med, King Gustaf V Res Inst, Unit Cardiol, S-17176 Stockholm, Sweden
[4] Karolinska Inst, Dept Med, King Gustaf V Res Inst, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden
关键词
D O I
10.1016/j.jaad.2005.11.1079
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis appears to have increased cardiovascular morbidity. The underlying pathogenetic mechanisms remain unclear. Multiple factors, including systemic inflammation, oxidative stress, aberrant lipid profile: and concomitant established risk factors, have been discussed. However, previous studies consist of heterogeneous patient materials, including persons With highly varying disease duration and treatment. Methods: Two-hundred patients were investigated at the onset of psoriasis, comparing plasma concentrations of lipids, lipoproteins, and apolipoproteins with those of matched controls (N = 285). Results: Psoriasis patients manifest significant lipid abnormalities. Specifically, patients had significantly higher cholesterol concentrations in the very-low-density lipoprotein and high-density-lipoprotein 0 fractions. Adjustment for established environmental risk factors did not affect the results. Limitation: The response rate among Control subjects Was low. However, in additional analysis of a random subset of nonresponders demonstrated no substantial differences in the main results. Conclusion: The study supports the notion that lipid abnormalities in psoriasis may be genetically determined rather acquired.
引用
收藏
页码:614 / 621
页数:8
相关论文
共 35 条
[1]   Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease [J].
Aprahamian, T ;
Rifkin, I ;
Bonegio, A ;
Hugel, B ;
Freyssinet, JM ;
Sato, K ;
Castellot, JJ ;
Walsh, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (08) :1121-1131
[2]  
Bjorkegren J, 1997, J LIPID RES, V38, P301
[3]  
Carlson K, 1973, J Clin Pathol Suppl (Assoc Clin Pathol), V5, P32
[4]   Psoriasis - epidemiology and clinical spectrum [J].
Christophers, E .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (04) :314-320
[5]  
Çimsit G, 1998, BRIT J DERMATOL, V138, P917
[6]   ETRETINATE THERAPY CAUSES INCREASES IN LIPID-LEVELS IN PATIENTS WITH PSORIASIS [J].
ELLIS, CN ;
SWANSON, NA ;
GREKIN, RC ;
GOLDSTEIN, NG ;
BASSETT, DR ;
ANDERSON, TF ;
VOORHEES, JJ .
ARCHIVES OF DERMATOLOGY, 1982, 118 (08) :559-562
[7]   Cytokine expression in advanced human atherosclerotic plaques:: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines [J].
Frostegård, J ;
Ulfgren, AK ;
Nyberg, P ;
Hedin, U ;
Swedenborg, J ;
Andersson, U ;
Hansson, GK .
ATHEROSCLEROSIS, 1999, 145 (01) :33-43
[8]   HYPERTRIGLYCERIDEMIA, TRIGLYCERIDE-RICH LIPOPROTEINS AND CORONARY HEART-DISEASE [J].
HAMSTEN, A .
BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1990, 4 (04) :895-922
[9]   DISEASE CONCOMITANCE IN PSORIASIS [J].
HENSELER, T ;
CHRISTOPHERS, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 32 (06) :982-986
[10]   An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein [J].
Koba, S ;
Hirano, T ;
Sakaue, T ;
Takeuchi, H ;
Adachi, M ;
Katagiri, T .
CORONARY ARTERY DISEASE, 2002, 13 (05) :255-262